Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-07-01-Speech-2-160"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-07-01"^^xsd:date2
dcterms:Is Part Of	lp_eu:Strengthening the European pharmaceutical industry in the interest of patients – proposals for action2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20030701.6.2-160"2
lpv:hasSubsequent	lp_eu:2003-07-01-Speech-2-1612
lpv:speaker	lp:Carlos Lage2
lpv:spokenAs	member; PECH (2002-01-17--2004-07-19)3 member; Delegation to the EU-Kazakhstan, EU-Kyrgyzstan and EU-Uzbekistan Parliamentary Cooperation Committees and Delegation for relations with Tadjikistan, Turkmenistan and Mongolia (2002-02-07--2004-07-19)3 vice-chair; PES (2002-01-17--2004-07-19)3 unknown; Partido Socialista (1999-07-20--2004-07-19)3 substitute; Committee on the Environment, Public Health and Consumer Policy (2002-01-30--2004-07-19)3
lpv:translated text	"Mr President, Commissioners, I congratulate you on the speech you have just given. I will confine myself merely to asking Commissioner Liikanen a few questions. At the start of his speech, he drew our attention to the state of the European pharmaceutical industry, pointing out that it is less competitive than it once was and that, although it is one of the most important industries in Europe, it has now lost its pre-eminence to the United States. I would like, then, to make a short comment to the effect that the future of Europe – Europe’s destiny – is being determined today above all in its laboratories and research centres. That is why Commissioner Liikanen’s observation left me troubled, more troubled than I already was. So I would ask him this: might the legislative framework under development in Europe and the inflexible system of research regulations in the field of biotechnology, for example, not constitute a major obstacle to European industry’s acquiring or recovering competitiveness? I know that this is not what many of my fellow Members wish to hear, who, for philosophical or ideological reasons, are imposing a virtual veto on biotech development, but I felt obliged to put this question to you, Commissioner."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph